A complex role of activin A in non-alcoholic fatty liver disease

American Journal of Gastroenterology

Volumn 104, Issue 9, 2009, Pages 2196-2205

  Yndestad, Arne ^a,f   Haukeland, John Willy ^c,f   Dahl, Tuva Børresdatter ^a   Bjøro, Kristian ^a,f   Gladhaug, Ivar Prydz ^a,f   Berge, Christ ^d   Damås, Jan Kristian ^a   Haaland, Terese ^b   Løberg, Else Marit ^b   Linnestad, Paul ^b   Birkeland, Kåre ^c,f   Konopski, Zbigniew ^c   Halvorsen, Bente ^a,f   Berge, Rolf Kristian ^d,e   Aukrust, Pl ^a,f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; AMINOTRANSFERASE; COLLAGEN; FATTY ACID SYNTHASE; FOLLISTATIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ACTIVINS; ADULT; CELL LINE, TUMOR; FATTY LIVER; FEMALE; FOLLISTATIN; GENE EXPRESSION; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 69949144215     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.318     Document Type: Article

References (42)

1. Bjornsson E, Angulo P. Non-alcoholic fatty liver disease. Scand J Gastroenterol 2007; 42: 1023-30.
2. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (Baltimore, MD) 2006; 44: 865-73.
3. Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-5.
4. Day CP, James OF. Steatohepatitis: a tale of two' hits' ? Gastroenterology 1998; 114: 842-5.
5. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (Baltimore, MD) 2003; 37: 917-23.
6. Seki S, Kitada T, Yamada T et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.
7. de Caestecker M. Th e transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 2004; 15: 1-11.
8. Ling N, Ying SY, Ueno N et al. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 1986; 321: 779-82.
9. Werner S, Alzheimer C. Roles of activin in tissue repair, fi brosis, and infl ammatory disease. Cytokine Growth Factor Rev 2006; 17: 157-71.
10. Wada W, Kuwano H, Hasegawa Y et al. Th e dependence of transforming growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology 2004; 145: 2753-9.
11. Endo D, Kogure K, Hasegawa Y et al. Activin A augments vascular endothelial growth factor activity in promoting branching tubulogenesis in hepatic sinusoidal endothelial cells. J Hepatol 2004; 40: 399-404.
12. Rodgarkia-Dara C, Vejda S, Erlach N et al. Th e activin axis in liver biology and disease. Mutat Res 2006; 613: 123-37.
13. Haukeland JW, Konopski Z, Linnestad P et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fi brosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2005; 40: 1469-77.
14. Executive Summary of Th e Th ird Report of Th e National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
15. Haukeland JW, Damas JK, Konopski Z et al. Systemic infl ammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL 2. J Hepatol 2006; 44: 1167-74.
16. Yndestad A, Holm AM, M ü ller F et al. Enhanced expression of infl ammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003; 60: 141-6.
17. Bremer J. Th e eff ect of fasting on the activity of liver carnitine palmitoyltransferase and its inhibition by malonyl-CoA. Biochim Biophys Acta 1981; 665: 628-31.
18. Roncari DA. Fatty acid synthase from human liver. Meth Enzymol 1981; 71: Pt C:73-9.
19. Skorve J, al-Shurbaji A, Asiedu D et al. On the mechanism of the hypolipidemic eff ect of sulfur-substituted hexadecanedioic acid (3-thiadicarboxylic acid) in normolipidemic rats. J Lipid Res 1993; 34: 1177-85.
20. Wergedahl H, Liaset B, Gudbrandsen OA et al. Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats. J Nutr 2004; 134: 1320-7.
21. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fi brogenesis. J Gastroenterol Hepatol 2007; 22: S79-84.
22. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract 2005; 2: 46-53.
23. Glosli H, Gudbrandsen OA, Mullen AJ et al. Down-regulated expression of PPARalpha target genes, reduced fatty acid oxidation and altered fatty acid composition in the liver of mice transgenic for hTNFalpha. Biochim Biophys Acta 2005; 1734: 235-46.
24. Allard JP, Aghdassi E, Mohammed S et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol 2008; 48: 300-7.
25. Puri P, Baillie RA, Wiest MM et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2007; 46: 1081-90.
26. Yuen MF, Norris S, Evans LW et al. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol 2002; 37: 233-8.
27. Patella S, Phillips DJ, de Kretser DM et al. Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis. J Hepatol 2001; 34: 576-83.
28. Schwall RH, Robbins K, Jardieu P et al. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology (Baltimore, MD) 1993; 18: 347-56.
29. Patella S, Phillips DJ, Tchongue J et al. Follistatin attenuates early liver fi brosis: eff ects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol 2006; 290: G137-44.
30. Jones KL, de Kretser DM, Patella S et al. Activin A and follistatin in systemic infl ammation. Mol Cell Endocrinol 2004; 225: 119-25.
31. Russell CE, Hedger MP, Brauman JN et al. Activin A regulates growth and acute phase proteins in the human liver cell line, HepG 2. Mol Cell Endocrinol 1999; 148: 129-36.
32. Smith C, Yndestad A, Halvorsen B et al. Potential anti-infl ammatory role of activin A in acute coronary syndromes. J Am Coll Cardiol 2004; 44: 369-75.
33. Han YP. Matrix metalloproteinases, the pros and cons, in liver fi brosis. J Gastroenterol Hepatol 2006; 21: S88-91.
34. Schuppan D, Ruehl M, Somasundaram R et al. Matrix as a modulator of hepatic fi brogenesis. Semin Liver Dis 2001; 21: 351-72.
35. Albanis E, Friedman SL. Antifi brotic agents for liver disease. Am J Transplant 2006; 6: 12-9.
36. De Bleser PJ, Niki T, Xu G et al. Localization and cellular sources of activins in normal and fi brotic rat liver. Hepatology (Baltimore, MD) 1997; 26: 905-12.
37. Yndestad A, Ueland T, ie E et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004; 109: 1379-85.
38. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
39. Fromenty B, Robin MA, Igoudjil A et al Th e ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30: 121-38.
40. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta 2000; 1486: 1-17.
41. Larter CZ, Yeh MM, Haigh WG et al. Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J Hepatol 2008; 48: 638-47.
42. Tanaka N, Sano K, Horiuchi A et al. Highly purifi ed eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 413-8.